1. Shedding light on macrophage immunotherapy in lung cancer.
- Author
-
Ma, Huiyun, Zhang, Zhouwei, Hu, Qin, Chen, Hongyu, Wu, Gujie, Zhou, Youlang, and Xue, Qun
- Subjects
LUNG cancer ,VASCULAR endothelial cells ,CANCER chemotherapy ,IMMUNE checkpoint inhibitors ,MACROPHAGES - Abstract
The search for therapeutic options for lung cancer continues to advance, with rapid advances in the search for therapies to improve patient prognosis. At present, systemic chemotherapy, immune checkpoint inhibitor therapy, antiangiogenic therapy, and targeted therapy for driver gene positivity are available in the clinic. Common clinical treatments fail to achieve desired outcomes due to immunosuppression of the tumor microenvironment (TME). Tumor immune evasion is mediated by cytokines, chemokines, immune cells, and other cells such as vascular endothelial cells within the tumor immune microenvironment. Tumor-associated macrophages (TAMs) are important immune cells in the TME, inducing tumor angiogenesis, encouraging tumor cell proliferation and migration, and suppressing antitumor immune responses. Thus, TAM targeting becomes the key to lung cancer immunotherapy. This review focuses on macrophage phenotype, polarization mechanism, role in lung cancer, and advances in macrophage centric immunotherapies. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF